Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

2018270 citationsJournal Articlehybrid Open Access

Authors

for the PORTEC Study Group · Leiden University Medical Center

Bastiaan G. Wortman · Leiden University Medical Center

Carien L. Creutzberg · Leiden University Medical Center

Hein Putter · Leiden University Medical Center

I.M. Jürgenliemk-Schulz · Medisch Spectrum Twente

Jan J. Jobsen · Medisch Spectrum Twente

Ludy Lutgens

Abstract

Long-term results of the PORTEC-2 trial confirm VBT as standard adjuvant treatment for HIR endometrial cancer. Molecular risk assessment has the potential to guide adjuvant therapy. EBRT provided better pelvic control in patients with unfavourable risk factors.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Ovarian cancer diagnosis and treatment Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 119, Issue 9, pp. 1067-1074

DOI: 10.1038/s41416-018-0310-8

Field-Weighted Citation Impact: 20.24